SCHEMBL5482094

SCHEMBL5482094

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3c2ccc(Cl)c3OC2CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.49
HTT P42858 2/20 0.34
CNR1 P21554 1/20 0.34
GPR35 Q9HC97 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
FAAH O00519 1/20 0.33
EPHX2 P34913 1/20 0.33
GLA P06280 1/20 0.32
LMNA P02545 2/20 0.31
RORC P51449 1/20 0.31
RAB9A P51151 2/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
KMT2A Q03164 1/20 0.30
IP6K1 Q92551 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
HPGD P15428 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5488442 0.85 MAPT (0.47) MAPTHTTCNR1GPR35GPR55
SCHEMBL5478000 0.84 CNR1 (0.46) HTTCNR1GPR35GPR55
SCHEMBL5478229 0.83 MAPT (0.54) MAPTHTTCNR1GPR35GPR55
SCHEMBL5482836 0.82 MAPT (0.50) MAPTHTTCNR1GPR35GPR55
SCHEMBL5482053 0.81 MAPT (0.56) MAPTHTTCNR1GPR35GPR55
SCHEMBL5480016 0.72 MAPT (0.48) MAPTHTTCNR1GPR35GPR55
SCHEMBL5477973 0.71 MAPT (0.62) MAPTHTTCNR1GPR35GPR55
SCHEMBL5480025 0.69 MAPT (0.39) MAPTHTTCNR1GPR35GPR55
SCHEMBL5479179 0.69 SMN1; SMN2 (0.53) MAPTHTTCNR1GPR35GPR55
SCHEMBL5475385 0.69 MAPT (0.36) MAPTHTTCNR1GPR35GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885HTT 1880/4885CNR1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.